David Bardsley joins Cresset Group

Takes newly created role of sales director

Cresset BioMolecular Discovery has appointed David Bardsley to the newly created role of sales director at the Cresset Group. The company, which develops software for calculating and comparing the molecular field characteristics of chemical compounds, is based in Welwyn Garden City, Hertfordshire, UK.

Bardsley joins Cresset from Synergy Health where he was sales director of the Healthcare Solutions division. He has more than 20 years of commercial experience in the scientific market.

Prior to working at Synergy Health, Bardsley was responsible for business development and strategic commercial growth with Symyx Technologies and CambridgeSoft.

You may also like

Analysis

Beckman introduces novel CE-Marked Hepatitis Assays at ESCMID Global

The HBsAg high positive algorithm eliminates the need for repeat and confirmatory testing for samples ≥ 100.00 S/CO
Analysis

Titan Enterprises’ 800-series turbine flow meters provide a low-cost solution for the pharmaceutical industry

Titan's flowmeters can assist in accurate batch delivery and dispensing systems for low viscosity liquids for incorporation in ingestible pharmaceutical products
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Analysis

IMPACT CKD model reveals the escalating toll of chronic kidney disease

The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Analysis

Landmark installation for the Vapourtec E-Series system

The landmark spreads the use of E-Series to 20 nations and comes in four standard configurations: easy-Scholar, easy-Polymer, easy-Medchem and easy-Photochem
Analysis

Bio-Rad and Oncocyte partner to commercialise transplant monitoring with Droplet Digital PCR

The collaboration aims to provide researchers with tools to enable transformational monitoring of key biomarkers in solid tissue transplants
Analysis

Preci and Biopredic International partner to optimise suspension hepatocyte assay systems

License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies
Subscribe now